Wanjia Group Holdings Ltd. has released its annual financial results for the year ended 31 March 2025. The Group reported a total revenue of approximately HK$161.693 million, marking a decrease of around 10.71% compared to the previous year's revenue of approximately HK$181.092 million. The decline was attributed primarily to the pharmaceutical wholesale and distribution business, which saw a slight revenue drop of approximately 2.03% to HK$50.491 million from HK$51.536 million in 2024. The Group recorded a loss from operations of HK$4.089 million, which is a significant improvement from the previous year's loss of HK$39.438 million. The finance costs also decreased to HK$1.403 million from HK$1.711 million in 2024. Consequently, the loss before taxation narrowed to HK$5.492 million, down from HK$41.149 million in the previous year. The Board has decided not to recommend the payment of a final dividend for the year ended 31 March 2025, consistent with the prior year. No specific outlook or guidance for the upcoming year has been provided in the report.